Real-World Characteristics of Patients with IgAN Receiving Combination Therapy: A Retrospective Claims Analysis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0660; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Methods This retrospective cohort study included adults (aged ≥18 years) who initiated ≥2 FDA-approved IgAN-specific therapies—targeted-release budesonide, sparsentan, iptacopan, and atrasentan—within 60 days of each other in the Komodo Healthcare Map™ database (Feb 1, 2023–Dec 4, 2025). Conclusion This study provides real-world evidence on characteristics of pts receiving a combination of IgAN-specific therapies, demonstrating the increasing adoption of multi-mechanistic treatment strategies in clinical practice. These findings align with KDIGO guideline recommendations emphasizing simultaneous targeting of complementary disease pathways in IgAN."
Combination therapy • Real-world • Real-world evidence • Retrospective data • Fibrosis • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Immunology
|
|
Helen Trenz; Briana C. Ndife; Ruth Haile-Meskale; Hamid Moradi; Raquel Skyla Erb; Shiwani Kumari Prasad; Rashmi Bhattacharjee; Margaret Helmuth; Laura H. Mariani
|